Logo image of SLGL

SOL-GEL TECHNOLOGIES LTD (SLGL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SLGL - IL0011417206 - Common Stock

58 USD
+2.32 (+4.17%)
Last: 1/9/2026, 8:26:52 PM
Fundamental Rating

4

SLGL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. SLGL has a great financial health rating, but its profitability evaluates not so good. SLGL shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SLGL had negative earnings in the past year.
SLGL had a negative operating cash flow in the past year.
In the past 5 years SLGL reported 4 times negative net income.
In the past 5 years SLGL always reported negative operating cash flow.
SLGL Yearly Net Income VS EBIT VS OCF VS FCFSLGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

The Return On Assets of SLGL (-8.68%) is better than 68.06% of its industry peers.
SLGL's Return On Equity of -10.70% is fine compared to the rest of the industry. SLGL outperforms 72.25% of its industry peers.
Industry RankSector Rank
ROA -8.68%
ROE -10.7%
ROIC N/A
ROA(3y)-40.55%
ROA(5y)-33.3%
ROE(3y)-47.5%
ROE(5y)-38.86%
ROIC(3y)N/A
ROIC(5y)N/A
SLGL Yearly ROA, ROE, ROICSLGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLGL Yearly Profit, Operating, Gross MarginsSLGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

8

2. Health

2.1 Basic Checks

SLGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SLGL remains at a similar level compared to 1 year ago.
SLGL has more shares outstanding than it did 5 years ago.
SLGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SLGL Yearly Shares OutstandingSLGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SLGL Yearly Total Debt VS Total AssetsSLGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

SLGL has an Altman-Z score of 5.59. This indicates that SLGL is financially healthy and has little risk of bankruptcy at the moment.
SLGL's Altman-Z score of 5.59 is fine compared to the rest of the industry. SLGL outperforms 75.39% of its industry peers.
There is no outstanding debt for SLGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.59
ROIC/WACCN/A
WACC8.6%
SLGL Yearly LT Debt VS Equity VS FCFSLGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 7.32 indicates that SLGL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.32, SLGL is in the better half of the industry, outperforming 71.73% of the companies in the same industry.
SLGL has a Quick Ratio of 7.32. This indicates that SLGL is financially healthy and has no problem in meeting its short term obligations.
SLGL has a better Quick ratio (7.32) than 72.25% of its industry peers.
Industry RankSector Rank
Current Ratio 7.32
Quick Ratio 7.32
SLGL Yearly Current Assets VS Current LiabilitesSLGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

SLGL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.91%.
The Revenue has grown by 62.04% in the past year. This is a very strong growth!
Measured over the past years, SLGL shows a very strong growth in Revenue. The Revenue has been growing by 64.25% on average per year.
EPS 1Y (TTM)-54.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2030%
Revenue 1Y (TTM)62.04%
Revenue growth 3Y-43.83%
Revenue growth 5Y64.25%
Sales Q2Q%-92.54%

3.2 Future

Based on estimates for the next years, SLGL will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.10% on average per year.
Based on estimates for the next years, SLGL will show a very strong growth in Revenue. The Revenue will grow by 94.55% on average per year.
EPS Next Y97.17%
EPS Next 2Y38.97%
EPS Next 3Y10.07%
EPS Next 5Y15.1%
Revenue Next Year870.39%
Revenue Next 2Y327.87%
Revenue Next 3Y56.77%
Revenue Next 5Y94.55%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SLGL Yearly Revenue VS EstimatesSLGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M
SLGL Yearly EPS VS EstimatesSLGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SLGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLGL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLGL Price Earnings VS Forward Price EarningsSLGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60 -80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLGL Per share dataSLGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.97%
EPS Next 3Y10.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLGL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SOL-GEL TECHNOLOGIES LTD

NASDAQ:SLGL (1/9/2026, 8:26:52 PM)

58

+2.32 (+4.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-20 2025-11-20/bmo
Earnings (Next)03-23 2026-03-23/amc
Inst Owners26.46%
Inst Owner Change0%
Ins Owners5.14%
Ins Owner ChangeN/A
Market Cap161.82M
Revenue(TTM)18.97M
Net Income(TTM)-3.41M
Analysts82.86
Price Target51 (-12.07%)
Short Float %1.93%
Short Ratio0.97
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)233.88%
Min Revenue beat(2)-15.77%
Max Revenue beat(2)483.54%
Revenue beat(4)2
Avg Revenue beat(4)119.23%
Min Revenue beat(4)-86.37%
Max Revenue beat(4)483.54%
Revenue beat(8)4
Avg Revenue beat(8)101.43%
Revenue beat(12)5
Avg Revenue beat(12)51.51%
Revenue beat(16)7
Avg Revenue beat(16)32.65%
PT rev (1m)0%
PT rev (3m)733.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2222.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-70%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-86.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)225.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.76
P/FCF N/A
P/OCF N/A
P/B 5.08
P/tB 5.08
EV/EBITDA N/A
EPS(TTM)-10.1
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-2.03
OCFYN/A
SpS8.58
BVpS11.43
TBVpS11.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.68%
ROE -10.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.55%
ROA(5y)-33.3%
ROE(3y)-47.5%
ROE(5y)-38.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.32
Quick Ratio 7.32
Altman-Z 5.59
F-Score4
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)23.47%
Cap/Depr(5y)26.73%
Cap/Sales(3y)4.34%
Cap/Sales(5y)3.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2030%
EPS Next Y97.17%
EPS Next 2Y38.97%
EPS Next 3Y10.07%
EPS Next 5Y15.1%
Revenue 1Y (TTM)62.04%
Revenue growth 3Y-43.83%
Revenue growth 5Y64.25%
Sales Q2Q%-92.54%
Revenue Next Year870.39%
Revenue Next 2Y327.87%
Revenue Next 3Y56.77%
Revenue Next 5Y94.55%
EBIT growth 1Y71.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.8%
OCF growth 3YN/A
OCF growth 5YN/A

SOL-GEL TECHNOLOGIES LTD / SLGL FAQ

Can you provide the ChartMill fundamental rating for SOL-GEL TECHNOLOGIES LTD?

ChartMill assigns a fundamental rating of 4 / 10 to SLGL.


What is the valuation status for SLGL stock?

ChartMill assigns a valuation rating of 0 / 10 to SOL-GEL TECHNOLOGIES LTD (SLGL). This can be considered as Overvalued.


Can you provide the profitability details for SOL-GEL TECHNOLOGIES LTD?

SOL-GEL TECHNOLOGIES LTD (SLGL) has a profitability rating of 1 / 10.


Can you provide the financial health for SLGL stock?

The financial health rating of SOL-GEL TECHNOLOGIES LTD (SLGL) is 8 / 10.